Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal
June 19, 2020 10:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Host its Annual Meeting of Stockholders in Virtual Format
May 27, 2020 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and...
Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference
May 26, 2020 09:00 ET
|
Optinose, Inc.
YARDLEY, Penn., May 26, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 14, 2020 16:15 ET
|
Optinose, Inc.
YARDLEY, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2020 Financial Results and Operational Updates
May 07, 2020 16:01 ET
|
Optinose, Inc.
Company reports first quarter 2020 XHANCE net revenue of $7.1 million First quarter 2020 XHANCE prescriptions increased 149% from first quarter 2019 Conference call and webcast to be held today at...
Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020
April 30, 2020 16:15 ET
|
Optinose, Inc.
Conference Call and Webcast Scheduled for Thursday, May 7 at 4:15 p.m. Eastern Time YARDLEY, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights
March 05, 2020 06:30 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2019 XHANCE net revenue of $11.1 million and $30.4 million Fourth quarter 2019 XHANCE prescriptions increased 26% from third quarter 2019 Company expects...
Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020
February 27, 2020 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Appoints Victor Clavelli as Chief Commercial Officer
February 19, 2020 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial
December 17, 2019 08:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...